Gamma Glutamyl Transferase Levels In Patients with Acute Coronary Syndrome: A Cross-Sectional Study

2017 ◽  
Vol 8 (4) ◽  
pp. 121-125
Author(s):  
Jain Jyoti ◽  
Verma Nitin ◽  
Banait Shashank ◽  
Desmukh Pradeep
Keyword(s):  
Acute Coronary Syndrome ◽  
Cross Sectional Study ◽  
Gamma Glutamyl Transferase ◽  
Sectional Study ◽  
Cross Sectional ◽  
Gamma Glutamyl ◽  
Coronary Syndrome ◽  
Glutamyl Transferase

STUDY ON EVALUATION OF SERUM GAMMA-GLUTAMYL TRANSFERASE (GGT) LEVELS IN ACUTE CORONARY SYNDROME

2021 ◽  
pp. 39-40
Author(s):  
Avtar Singh Dhanju ◽  
Deepshikha Singla ◽  
Pashaura Singh ◽  
Ajay Chhabra ◽  
Sukhraj Kaur
Keyword(s):  
Acute Coronary Syndrome ◽  
Cross Sectional Study ◽  
Gamma Glutamyl Transferase ◽  
Cross Sectional ◽  
Gamma Glutamyl ◽  
Coronary Syndrome ◽  
Healthy Control ◽  
Group A ◽  
Group B ◽  
Glutamyl Transferase

Aim: The present study was undertaken with the aim to evaluate serum Gamma Glutamyl Transferase (GGT) levels in patients of acute coronary syndrome. Methodology: This cross-sectional study was conducted on 50 cases with acute coronary syndrome (Group A) and 50 healthy control subjects (Group B) meeting inclusion and exclusion criteria. Results: There is signicant rise in serum GGT levels in patients presenting with ACS in Group A as compared to Group B. Conclusion: Higher levels of GGT in ACS patients with risk factors such as hypertension, dyslipidemia and smoking may serve as biomarker to predict the occurrence of ACS.

scholarly journals Chest discomfort at night and risk of acute coronary syndrome: cross-sectional study of telephone conversations

2020 ◽  
Vol 37 (4) ◽  
pp. 473-478 ◽  
Author(s):  
Loes T Wouters ◽  
Dorien L Zwart ◽  
Daphne C Erkelens ◽  
Noël S Cheung ◽  
Esther de Groot ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Risk Ratio ◽  
Patient Characteristics ◽  
Final Diagnosis ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Chest Discomfort ◽  
Cross Sectional ◽  
Adjusted Risk ◽  
Coronary Syndrome

Abstract Background During telephone triage, it is difficult to assign adequate urgency to patients with chest discomfort. Considering the time of calling could be helpful. Objective To assess the risk of acute coronary syndrome (ACS) in certain time periods and whether sex influences this risk. Methods Cross-sectional study of 1655 recordings of telephone conversations of patients who called the out-of-hours services primary care (OHS-PC) for chest discomfort. Call time, patient characteristics, symptoms, medical history and urgency allocation of the triage conversations were collected. The final diagnosis of each call was retrieved at the patient’s general practice. Absolute numbers of patients with and without ACS were plotted and risks per hour were calculated. The risk ratio of ACS at night (0 to 9 am) was calculated by comparing to the risk at other hours and was adjusted for gender and age. Results The mean age of callers was 58.9 (standard deviation ±19.5) years, 55.5% were women and, in total, 199 (12.0%) had an ACS. The crude risk ratio for an ACS at night was 1.80 (confidence interval 1.39–2.34, P < 0.001): 2.33 (1.68–3.22, P < 0.001) for men and 1.29 (0.83–1.99, P = 0.256) for women. The adjusted risk ratio for ACS of all people at night was 1.82 (1.07–3.10, P = 0.039). Conclusions Patients calling the OHS-PC for chest discomfort between 0 and 9 am have almost twice a higher risk of ACS than those calling other hours, a phenomenon more evident in men than in women. At night, dispatching ambulances more ‘straightaway’ could be considered for these patients with chest discomfort. Trial number NTR7331.

scholarly journals Frequency of CYP2C19*2 Allele in Patients with Acute Coronary Syndrome: A Cross-sectional Study from Central Kerala, India

2021 ◽  
Author(s):  
Christina Ann George ◽  
Shibu Thadathil Sreedharan ◽  
Smitha Kalarikkal Satheesan ◽  
Sindhu Panakkaparambil Surendranath
Keyword(s):  
Acute Coronary Syndrome ◽  
Cross Sectional Study ◽  
Government Medical College ◽  
Sectional Study ◽  
Therapy Failure ◽  
Cross Sectional ◽  
Medical College ◽  
Coronary Syndrome ◽  
Variant Genotype ◽  
Study Population

Introduction: Ischaemic Heart Diseases (IHD) are increasing at an alarming rate globally. Pharmacotherapy, the mainstay of management of IHD, has Dual Antiplatelet Therapy (DAPT) at its crux. DAPT, comprising of clopidogrel and aspirin, is used often for 12 months in medically managed Acute Coronary Syndrome (ACS). Clopidogrel being a prodrug, needs to be activated after ingestion, mainly by Cytochrome family of enzymes, for the desired pharmacological effects. Abnormal enzymes that convert clopidogrel to its active form can reduce the effectiveness of the drug. Therefore, Single Nucleotide Polymorphisms (SNPs) of the enzymes involved, would predispose the patient to therapy failure and recurrence of the illness. This study aims at identifying the presence of a genetic variant associated with clopidogrel responsiveness in patients with ACS. Aim: To estimate the frequency of CYP2C19*2 allele in patients with ACS presenting to Government Medical College, Thrissur, Kerala, India. Materials and Methods: Present study was a cross-sectional study done among 60 patients who presented to Government Medical College, Thrissur with ACS, between June 2018 to June 2019. Having obtained informed consent from the participants blood samples were collected in Ethylene diamine tetra-acetic Acid (EDTA) tubes. Samples were used to look for presence of CYP2C19*2 allele by Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP). Results: Out of 60 patients 38 were males and 22 were females. Most common age group was 61-65 years. The frequency of CYP2C19*2 allele was 41% in the study population and the variant genotype (AA/AG) was present in 62%. Conclusion: The variant genotype was found to be present in a high frequency in the study population implying the high risk for therapy failure in the study population. This asserts the need to probe the matter further, as the gene is also implicated in the metabolism of several other drugs. The introduction of pharmacogenomic testing prior to initiation of therapy may be therefore recommended for better treatment outcome. However, to validate the same, further studies with larger sample size may be necessary.

Sign in / Sign up

Export Citation Format

Share Document